Thymic stromal lymphopoietin levels after allogeneic hematopoietic stem cell transplantation
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Thymic stromal lymphopoietin levels after allogeneic hematopoietic stem cell transplantation. / Møller, Dina Leth; Kielsen, Katrine; Nielsen, Claus Henrik; Sengeløv, Henrik; Pedersen, Anders Elm; Ryder, Lars Peter; Müller, Klaus.
In: Immunopharmacology and Immunotoxicology, Vol. 44, No. 6, 2022, p. 1004-1012.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Thymic stromal lymphopoietin levels after allogeneic hematopoietic stem cell transplantation
AU - Møller, Dina Leth
AU - Kielsen, Katrine
AU - Nielsen, Claus Henrik
AU - Sengeløv, Henrik
AU - Pedersen, Anders Elm
AU - Ryder, Lars Peter
AU - Müller, Klaus
N1 - Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Background: Thymic stromal lymphopoietin (TSLP) is an immunoregulatory, Th2-polarizing cytokine produced by epithelial cells. We hypothesized that TSLP affects immune reconstitution after hematopoietic stem cell transplantation (HSCT) leading to increased alloreactivity. Methods: We measured plasma TSLP by ELISA in 38 patients and assessed the immune reconstitution by flow cytometry. Results: TSLP levels rose after initiation of the conditioning to peak at day +21 after HSCT (p =.03), where TSLP levels correlated with counts of neutrophils (rho = 0.36, p =.04), monocytes (rho = 0.58, p =.006), and lymphocytes (rho = 0.59, p =.02). Overall absolute TSLP levels were not associated with acute or chronic graft-vs-host disease (a/cGvHD). However, patients mounting a sustained increase in TSLP levels at day +90 had a higher risk of cGvHD compared to patients who had returned to pre-conditioning levels at that stage (cumulative incidence: 77% vs. 38%, p =.01). Conclusion: In conclusion, this study suggests a role of TSLP in immune reconstitution and alloreactivity post-HSCT. lymphopoietin (TSLP) is an immunoregulatory, Th2-polarizing cytokine produced by epithelial cells. We hypothesized that TSLP affects immune reconstitution after hematopoietic stem cell transplantation (HSCT) leading to increased alloreactivity. We measured plasma TSLP by ELISA in 38 patients and assessed the immune reconstitution by flow cytometry.
AB - Background: Thymic stromal lymphopoietin (TSLP) is an immunoregulatory, Th2-polarizing cytokine produced by epithelial cells. We hypothesized that TSLP affects immune reconstitution after hematopoietic stem cell transplantation (HSCT) leading to increased alloreactivity. Methods: We measured plasma TSLP by ELISA in 38 patients and assessed the immune reconstitution by flow cytometry. Results: TSLP levels rose after initiation of the conditioning to peak at day +21 after HSCT (p =.03), where TSLP levels correlated with counts of neutrophils (rho = 0.36, p =.04), monocytes (rho = 0.58, p =.006), and lymphocytes (rho = 0.59, p =.02). Overall absolute TSLP levels were not associated with acute or chronic graft-vs-host disease (a/cGvHD). However, patients mounting a sustained increase in TSLP levels at day +90 had a higher risk of cGvHD compared to patients who had returned to pre-conditioning levels at that stage (cumulative incidence: 77% vs. 38%, p =.01). Conclusion: In conclusion, this study suggests a role of TSLP in immune reconstitution and alloreactivity post-HSCT. lymphopoietin (TSLP) is an immunoregulatory, Th2-polarizing cytokine produced by epithelial cells. We hypothesized that TSLP affects immune reconstitution after hematopoietic stem cell transplantation (HSCT) leading to increased alloreactivity. We measured plasma TSLP by ELISA in 38 patients and assessed the immune reconstitution by flow cytometry.
KW - alloreactivity
KW - chronic GvHD
KW - hematopoietic stem cell transplantation
KW - immune reconstitution
KW - Thymic stromal lymphopoietin
U2 - 10.1080/08923973.2022.2102989
DO - 10.1080/08923973.2022.2102989
M3 - Journal article
C2 - 35899395
AN - SCOPUS:85135156343
VL - 44
SP - 1004
EP - 1012
JO - Immunopharmacology and Immunotoxicology
JF - Immunopharmacology and Immunotoxicology
SN - 0892-3973
IS - 6
ER -
ID: 316065097